Literature DB >> 17721272

p16INK4a expression in invasive vulvar squamous cell carcinoma.

Barbara Tringler1, Christoph Grimm, Grazyna Dudek, Robert Zeillinger, Clemens Tempfer, Paul Speiser, Elmar Joura, Alexander Reinthaller, Lukas A Hefler.   

Abstract

p16, a member of the INK4a family of cyclin-dependent kinase inhibitors, is known as a negative regulator of cell cycle progression and differentiation. Although p16 has been shown to be a promising biomarker for the detection of cervical intraepithelial neoplasia, few data have been published on vulvar cancer. Using immunohistochemistry, we evaluated the expression of p16 in 80 cases of invasive vulvar squamous cell carcinoma. Results were correlated with clinicopathologic parameters and survival data to determine the prognostic significance of p16 in vulvar cancer. p16 expression was detected in 34 of 80 (43%) cases of invasive vulvar squamous cell carcinoma. The expression was localized to the cytoplasm and the nuclei of the tumor cells. Correlations between p16 expression status and any clinicopathologic variables failed to be of statistical significance. In a univariate analysis, groin lymph node status, tumor stage, and tumor grade were associated with disease-free and overall survival, respectively. Patients positive for p16 expression showed a significantly longer disease-free and overall survival by univariate analysis. p16 expression was not associated with survival in a multivariate Cox-regression model. Our data add on those published in the literature and suggest that p16 may be of prognostic significance in invasive vulvar squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17721272     DOI: 10.1097/01.pai.0000213118.81343.32

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  9 in total

1.  HIV positivity but not HPV/p16 status is associated with higher recurrence rate in anal cancer.

Authors:  Joshua E Meyer; Vinicius J A Panico; Heloisa M F Marconato; David L Sherr; Paul Christos; Edyta C Pirog
Journal:  J Gastrointest Cancer       Date:  2013-12

2.  Cell cycle suppressor proteins are not related to HPV status or clinical outcome in patients with vulvar carcinoma.

Authors:  André Mourão Lavorato-Rocha; Iara Sant'ana Rodrigues; Beatriz de Melo Maia; Mônica Maria Ágata Stiepcich; Glauco Baiocchi; Kátia Cândido Carvalho; Fernando Augusto Soares; José Vassallo; Rafael Malagoli Rocha
Journal:  Tumour Biol       Date:  2013-07-06

3.  The overexpression of p16 is not a surrogate marker for high-risk human papilloma virus genotypes and predicts clinical outcomes for vulvar cancer.

Authors:  Jacek J Sznurkowski; Anton Żawrocki; Wojciech Biernat
Journal:  BMC Cancer       Date:  2016-07-13       Impact factor: 4.430

4.  Survival and failure types after radiation therapy of vulvar cancer.

Authors:  Christina Steen Vorbeck; Ivan Richter Vogelius; Marie Louise Vorndran Cøln Banner-Voigt; Hanne From Mathiesen; Mansoor Raza Mirza
Journal:  Clin Transl Radiat Oncol       Date:  2017-07-07

5.  Prognostic Value of Overexpressed p16INK4a in Vulvar Cancer: A Meta-Analysis.

Authors:  Hanyu Cao; Si Wang; Zhenyu Zhang; Jiangyan Lou
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

6.  Local immune response depends on p16INK4a status of primary tumor in vulvar squamous cell carcinoma.

Authors:  Jacek J Sznurkowski; Anton Żawrocki; Wojciech Biernat
Journal:  Oncotarget       Date:  2017-07-11

7.  HPV prevalence in vulvar cancer in Austria.

Authors:  Sophie Pils; Lisa Gensthaler; Laia Alemany; Reinhard Horvat; Silvia de Sanjosé; Elmar A Joura
Journal:  Wien Klin Wochenschr       Date:  2017-09-07       Impact factor: 1.704

8.  The impact of p16ink4a positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study.

Authors:  Lisa Gensthaler; Elmar A Joura; Laia Alemany; Reinhard Horvat; Silvia de Sanjosé; Sophie Pils
Journal:  Arch Gynecol Obstet       Date:  2020-01-22       Impact factor: 2.344

9.  The Clinical Relevance of p16 and p53 Status in Patients with Squamous Cell Carcinoma of the Vulva.

Authors:  Ellen L Barlow; Neil Lambie; Mark W Donoghoe; Zin Naing; Neville F Hacker
Journal:  J Oncol       Date:  2020-03-24       Impact factor: 4.375

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.